Using a chemical already in the body that breakdowns fat, Kybella targets fat in the chin area. The active ingredient in the injectable treatment is deoxycholic acid. In Kybella, the acid targets and destroys fat cells in the chin area, an alternative to liposuction and other surgical options in cases of moderate to severe fat below the chin. So far, Kybella only has approval for use in the under-chin (submental) area. It’s still under study for use elsewhere in the body.
No, not at all. Comparatively, Kybella is much different. Botox and related products relax hyperactive muscles that aggravate expression lines and dermal fillers smooth the appearance of skin by physically supporting it from the inner layers. Kybella improves appearance by destroying fat tissue, which is then flushed naturally by the body. In most areas of the face, problems usually arise from too little subdermal tissue, not too much, as is the case with double chins.
Yes. The most common are like those that may happen with any injection procedure. The area surrounding the injection point may become red, swollen, bruised, numb, or sore. Numbness may occur more frequently with Kybella, but its effects are temporary.
There’s potential for a more substantial problem with Kybella when it’s injected too close to the marginal mandibular nerve. If the drug affects this nerve, facial balance may be lost, since the nerve helps control facial expressions. A crooked smile could become quite literal. In testing of more than 5,000 patients, this occurred with about 4% of the study group. The effect is temporary and passed in all cases. However, this potential nerve effect remains part of the reason why the FDA limits Kybella treatments to the chin area.